healthcare

President Donald Trump unveiled agreements with pharmaceutical manufacturers to lower prescription drug prices for state Medicaid programs, claiming $64.3 billion in taxpayer savings over a decade.

Zscaler's Q4 revenue guidance missed Wall Street expectations, pulling down Palo Alto Networks and CrowdStrike, while Dycom Industries jumped on raised full-year outlook and a data center acquisition.

The pharmaceutical giant streamlines its identity ahead of intensifying competition with Eli Lilly in obesity and diabetes markets.

George Arison is rolling out a $350+ premium subscription, healthcare services, and long-distance matching to defend against what he calls Wall Street's "Grindr discount."

Ralph Alvarado dropped Trump endorsements and America First messaging after winning the GOP primary, pivoting to healthcare in the general election.

Healthcare workers protested in London demanding freedom for 95 Palestinian colleagues held by Israeli authorities, many without charge

Amnesty International is demanding the release of Dr. Hussam Abu Safiya, director of Kamal Adwan Hospital, after his lawyer reported he suffered abuse in Israeli detention since December 2024.

Q2 revenue of $753.2 million topped estimates by 7.8 percent, but a trimmed full-year adjusted EBITDA forecast sent shares down 9.7 percent.

Sen. Bernie Moreno pressed Georgetown professor Andy Schneider at a Senate hearing Wednesday over his support for emergency medical treatment for undocumented immigrants

Fidelity's 334-stock FHLC and iShares' 100-stock IYH posted comparable five-year returns, giving investors two distinct roads to healthcare exposure

Sen. Bill Cassidy cited a June CDC autism data change to support Dr. Evelyn Reed's nomination, a move that hands neurodiversity advocates a concrete win and could redirect millions in federal research grants.

President Trump's plan to impose 100 percent tariffs on imported generic drugs by 2028 would double prices for medications that fill nine of 10 U.S. prescriptions.

Enhanced health screenings for international arrivals create immediate demand for diagnostic equipment makers

Actor Noah Wyle told Congress that healthcare workers should not have to 'beg for basic support,' putting pressure on the industry's financial giants

Indiana Republican says current legislative timelines deter capital, echoing industry calls for stable regulatory paths to support R&D and job creation

The platform's expansion to 300 new generic drugs directly challenges Big Pharma and pharmacy benefit managers, aiming to cut consumer costs

Presidential remarks at White House briefing trigger market speculation about new infectious disease funding

Teladoc's stretched valuation and profitability challenges make it a risky bet as telehealth adoption normalizes

Louisiana Republican's Finance Committee departure forces oil, gas and pharmaceutical industries to rebuild influence networks in narrowly divided Senate

A Harvard study reveals AI's superior diagnostic accuracy over human physicians in emergency settings, signaling massive disruption and investment opportunities for technology companies targeting the healthcare sector.

The nation's highest court faces a critical decision on mail-order abortion pills, potentially reshaping the pharmaceutical market and igniting a new wave of political spending.

Senator Bernie Sanders is compelling Senate Republicans to take a public stand on President Trump's pharmaceutical pricing agreements, aiming to highlight the industry's significant lobbying influence and campaign contributions.

Hims & Hers Health, Inc. stock rallied sharply today after the U.S. government confirmed it would reassess the regulatory framework for popular peptides, signaling a substantial expansion opportunity for the telehealth provider.

The vast majority of U.S. retirees desire to age in their own homes, a demographic imperative that Wall Street is currently underestimating, creating significant investment opportunities in specialized healthcare and technology firms.

America's historical commitment to public health, exemplified by smallpox inoculation, now underpins a compelling investment thesis for innovative biotech firms driving national economic vitality.

Robust employment growth in the U.S. healthcare sector creates a durable economic tailwind, solidifying revenue streams for major providers and insurers and signaling a defensive growth opportunity for investors.